KRAS and colorectal carcinoma: The mutation status of KRAS gene in the codons 12 and 13 was documented as one of the predictive markers in the assessment of the competency of targeted therapy for patients of progressive CRC, when using cetuximab or panitumumab as therapeutic monoclonal antibodies [88].